Overview

A Study of ALS-008176 in Infants Hospitalized With RSV

Status:
Completed
Trial end date:
2018-02-15
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV)
Phase:
Phase 1
Details
Lead Sponsor:
Alios Biopharma Inc.